121 related articles for article (PubMed ID: 38615930)
1. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma.
Liang JH; Wang WT; Wang R; Gao R; Du KX; Duan ZW; Zhang XY; Li Y; Wu JZ; Yin H; Shen HR; Wang L; Li JY; Guo JR; Xu W
Cancer Lett; 2024 Jun; 591():216877. PubMed ID: 38615930
[TBL] [Abstract][Full Text] [Related]
2. An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
Liu L; Yan H; Ruan M; Yang H; Wang L; Lei B; Sun X; Chang C; Huang G; Xie W
Cancer Sci; 2021 Aug; 112(8):3083-3098. PubMed ID: 34033176
[TBL] [Abstract][Full Text] [Related]
3. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
4. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F; Hwang I; Sloan S; Hinterschied C; Helmig-Mason J; Long M; Chan WK; Prouty A; Chung JH; Zhang Y; Singh S; Youssef Y; Bhagwat N; Chen Z; Chen-Kiang S; Di Liberto M; Elemento O; Sehgal L; Alinari L; Vaddi K; Scherle P; Lapalombella R; Paik J; Baiocchi RA
Blood Adv; 2023 Oct; 7(20):6211-6224. PubMed ID: 37327122
[TBL] [Abstract][Full Text] [Related]
6. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
7. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
[TBL] [Abstract][Full Text] [Related]
8. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract][Full Text] [Related]
9. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
[TBL] [Abstract][Full Text] [Related]
10. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
11. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours.
Yuan HF; Zhao M; Zhao LN; Yun HL; Yang G; Geng Y; Wang YF; Zheng W; Yuan Y; Song TQ; Niu JQ; Zhang XD
Acta Pharmacol Sin; 2022 Sep; 43(9):2373-2385. PubMed ID: 35046516
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
14. The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
Zhang X; Wu J; Wu C; Chen W; Lin R; Zhou Y; Huang X
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):337-342. PubMed ID: 30446222
[TBL] [Abstract][Full Text] [Related]
15. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer.
Chakraborty PK; Xiong X; Mustafi SB; Saha S; Dhanasekaran D; Mandal NA; McMeekin S; Bhattacharya R; Mukherjee P
Oncotarget; 2015 Nov; 6(35):37367-84. PubMed ID: 26452259
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC
PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060
[TBL] [Abstract][Full Text] [Related]
17. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
[TBL] [Abstract][Full Text] [Related]
18. SREBP1/FASN/cholesterol axis facilitates radioresistance in colorectal cancer.
Jin Y; Chen Z; Dong J; Wang B; Fan S; Yang X; Cui M
FEBS Open Bio; 2021 May; 11(5):1343-1352. PubMed ID: 33665967
[TBL] [Abstract][Full Text] [Related]
19. PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-κB pathway.
Zhang L; Shao G; Shao J; Zhao J
Tissue Cell; 2022 Jun; 76():101788. PubMed ID: 35339800
[TBL] [Abstract][Full Text] [Related]
20. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Pal S; Baiocchi RA; Byrd JC; Grever MR; Jacob ST; Sif S
EMBO J; 2007 Aug; 26(15):3558-69. PubMed ID: 17627275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
